Skip to main content

September quarter report: Rakesh Jhunjhunwala raises stake in 4 firms, pares exposure in Titan Company

Rakesh Jhunjhunwala and partner RARE Enterprises increased stake in NCC, Agro Tech Foods and long-time favourite Lupin. For the first time, Jhunjhunwala has taken his stake over 1% in Tata Motors.

Small and midcap stocks that bucked the trend in the September quarter were on the radar of ace investor Rakesh Jhunjhunwala as well who raised stake in four firms and reduced it marginally in Titan Company, data collated by AceEquity. He left his stake unchanged in 10 companies.

Indian markets reversed the trend after hitting a low in March to reclaim crucial resistance levels on the way up. The Nifty50 rallied over 9 percent in the September quarter and there was plenty of action in individual stocks in the small & midcap space.

Jhunjhunwala invests in Indian companies under the following names: Jhunjhunwala Rakesh Radheshyam, Jhunjhunwala Rekha Rakesh, Rakesh Jhunjhunwala (in a personal capacity), Rekha Rakesh Jhunjhunwala and RAKESH JHUNJHUNWALA (as a partner of RARE Enterprises).

Jhunjhunwala and RARE Enterprises increased stake in NCC, Agro Tech Foods, and long-time favourite Lupin, the data as on October 16 shows. He also raised his stake to over 1 percent for the first time in Tata Motors.

Going by the year-to-date figures, Tata Motors has been an underperformer but has recouped most of the losses in the last six months, rallying by about 80 percent since March, data shows.

On October 1, Tata Motors reported a 5.09 percent increase in sales to 1,10,379 units in the second quarter of the current fiscal. The company sold a total of 1,05,031 units in the same period last fiscal, Tata Motors said in a statement.

Here is a list of 15 companies in Rakesh Jhunjhunwala's portfolio that have released shareholding data for the September quarter as of October 16, 2020. Please note that this may or may not be an exhaustive list of Jhunjhunwala’s portfolio but only a list of companies in which he holds over 1 percent stake.  



The big bull reduced stake in Titan Company after his wife, Rekha, sold 50,000 shares in the September quarter, according to a regulatory filing.

The recent business updated posted by the company is encouraging. The management has reassured investors that the business is returning to normal, thanks to the recovery in sales in its jewellery division in the September quarter.

Titan's major revenue and EBIDTA come from the jewellery segment, which is highly sensitive to the macro-economic scenario, brokerages say. Reports indicate that Tanishq revenue has recovered to 90 percent of pre-COVID levels, significantly ahead of consensus expectations.

Jhunjhunwala kept his stake constant in 10 companies. Nine of the companies that reported their shareholding data have given positive returns of up to 155 percent in the last six months.

Companies in which Jhunjhunwala maintained his stake are Firstsource Solutions, Geojit Financial Services, MCX, Man InfraConstruction Ltd, CRISIL, Aptech, Orient Cement, The Indian Hotel Company, Fortis Healthcare and Anant Raj.

 

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more